Michel Vounatsos (Credit: World Economic Forum/Ciaran McCrickard)
Alzheimer's quick OK, take two: FDA offers Biogen, Eisai a shortcut to a possible lecanemab approval
Biogen CEO Michel Vounatsos is departing under a dark and wide cloud created by the Aduhelm fiasco, which essentially destroyed any hope of any substantial …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.